Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)
Por:
Villalba A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, Arnao M, Arguiñano JM, Jimenez M, Canet M, Teruel AI, Sola M, Díaz FJ, Encinas C, Garcia A, Rosiñol L, Suárez A, Gonzalez MS, Izquierdo I, Hernández MT, Infante MS, Sánchez MJ, Sampol A and de la Rubia J
Publicada:
6 dic 2022
Ahead of Print:
1 sep 2022
Resumen:
Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having >= 1 of the following: del17p, t(4;14), t(14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10-82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT (p = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic.
Filiaciones:
Villalba A:
Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Gonzalez-Rodriguez AP:
Hematology Department, Hospital Universitario Central de Asturias-HUCA Oviedo, Oviedo, Spain
Arzuaga-Mendez J:
Hematology Department, Grupo de Cáncer Hematológico, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain
Puig N:
Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
Arnao M:
Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Arguiñano JM:
Hematology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
:
Hematology Department, Hospital Universitario Dr. Peset, Valencia, Spain
Canet M:
Hematology Department, Hospital Universitari Mútua Terrasa, Terrasa, Spain
Teruel AI:
Hematology Department, Hospital Clínico Universitario, Valencia, Spain
Sola M:
Hematology Department, Hospital Universitario Morales Meseguer, Murcia, Spain
Díaz FJ:
Hematology Department, Hospital Universitario de Burgos, Burgos, Spain
Encinas C:
Hematology Department, Hospital General Universitario Gregorio Marañón (HGUGM), IiSGM, Madrid, Spain
Garcia A:
Hematology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain
Rosiñol L:
Hematology Department, Hospital Clínic, Barcelona, Spain
Suárez A:
Hematology Department, Hospital de Gran Canaria Doctor Negrín, Las Palmas de Gran Canarias, Municipality of Las Palmas, Spain
Gonzalez MS:
Hematology Department, H. Clínico Universitario Santiago de Compostela, La Coruña, Spain
Izquierdo I:
Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
Hernández MT:
Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Infante MS:
Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
Sánchez MJ:
Hematology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
Sampol A:
Hematology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
de la Rubia J:
Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Hematology Department, Universidad Católica "San Vicente Mártir", Valencia, Spain
CIBERONC CB16/12/00284, Valencia, Spain
|